Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine + Clofarabine vs Decitabine in Higher Risk MDS
NCT00903760Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2010
- Primary completion
- Jun 2015
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of clofarabine in myelodysplastic syndrome (MDS) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Event Free Survival at 1 year. Started Jan 2010; status: completed.
02
Drugs
clofarabine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00903760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00903760.